Aspectos críticos do abuso de hormônios protéicos no exercício e no esporte: atualização

Carlos Kusano Bucalen Ferrari

doi:10.31053/1853.0605.v70.n3.20227

Autores/as

Carlos Kusano Bucalen Ferrari Biomedical Nutritional and Epidemiologic Research Group (BIONUTRE), Campus Universitário do Araguaia, Universidade Federal de Mato Grosso (UFMT).

DOI:

https://doi.org/10.31053/1853.0605.v70.n3.20227

Palabras clave:

IGF-1, insulina, diabetes, hipertensão, hipotireoidismo

Resumen

O abuso de hormônios em praticantes de exercícios físicos é muito difundido. Muitas pessoas crêem que estas substâncias podem promover hipertrofia muscular e melhoria da forma física sem trazer prejuízos à saúde. Porém, este é apenas mais um mito desmascarado pela ciência. Este artigo atualiza informações sobre o abuso de insulina, hormônio do crescimento, hormônios da tireóide e eritropoetina. O abuso de hormônios protéicos (peptídicos) pode causar paralisia motora, lesão e perda de massa muscular, diabetes mellitus, hipotireoidismo, hipertensão arterial, sudorese, dores de cabeça, vômitos e aumenta o risco de aterosclerose, trombose, osteoporose e câncer.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

1. Tavares, O. Notas para uma análise da produção em Ciências Sociais sobre doping no esporte. Esporte Soc; 2006, 1(2) Março/Junho. Disponível em URL: [http://www.lazer.eefd.ufrj.br/espsoc/html/es206.html]. [13/10/2012].

2. Maughan R, Gleeson M, Greenhaff PL. Bioquímica do exercício e do treinamento. São Paulo, Editora Manole, 2001.

3. Bucci M, Vinagre EC, Campos GER, Curi R, Pithon-Curi TC. Efeitos do treinamento concomitante sob a hipertrofia e endurance no músculo esquelético. Rev Brasil Ciênc Movim; 2005; 13: 17-28.

4. Clement PB, Young RH, Scully RE. Diffuse, perinodular, and other patterns of hydropic degeneration within and adjacent to uterine leiomyomas. Problems in differential diagnosis. Am J Pathol; 1992, 16: 26-32.

5. Camargo JLV de, Oliveira DE de (Orgs). Patologia Geral. Abordagem Multidisciplinar. Rio de Janeiro, Editora GuanabaraKoogan, 2007. p.39-40.

6. Raw I, Ho PL. Integração e seus sinais. São Paulo, Editora UNESP, 1999. p.95-98.

7. Costanzo LS. Fisiologia endócrina. In: Fisiologia. Rio de Janeiro, 2ªed., Editora Elsevier, 2004, Cap. 9, p. 359-421.

8. Green GA. Insulin as an anabolic drug of abuse in sport? Diab Technol Therap 2004, 6: 387-388.

9. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur J Inter Med; 2006, 17: 479-484.

10. Endre T, Mattiasson I, Berglund G, Hulthein UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension; 1994, 23: 313-319.

11. Ferrari CKB. Fisiopatologia e Clínica da Síndrome metabolica. Arq Catar Med 2007; 36(4): 90-95.

12. Elkin SL, Brady AS, Williams IP. Bodybuilders find it easy to obtain insulin to help them in training. British Medical Journal, 1997; 314: 1280.

13. Boileau P, Aboumrad B, Bougnères P. Recurrent comas due to secret self-administration of insulin in adolescents with type I diabetes. Diabetes Care 2006; 29: 430-431.

14. Ganong WF. Fisiologia médica. Rio de Janeiro, Editora McGraw-Hill Interamericana do Brasil, 2007.

15. Adams GR. Insulin-like growth factor in muscle growth and its potential abuse by athletes. Brit J Sport Med, 2000; 34: 412-413.

16. Ehrnborg C, Ellegård L, Bosaeus I, Bengtsson B-Å, Rosén T. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin Endocrinol 2005; 62: 449-457.

17. Meinhardt U, Nelson AE, Hansen JL, Birzniece V, Clifford D, Leung K-C, Graham K, Ho KKY. The effects of growth hormone on body composition and physical performance in recreational athletes. Ann Intern Med 2010; 152: 568-577.

18. Doessing S, Kjaer M. Growth hormone and connective tissue in exercise. Scand J Med Sci Sport 2005; 15(4): 202-210.

19. Anatomical Chart Company. Atlas de Fisiopatologia. Rio de Janeiro, Editora Guanabara-Koogan, 2004.

20. Ashraf A, McCormick K. Hyperreninemia and hypoaldosteronism in a child with short stature. Endocrinologist 2004; 14: 313-316.

21. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics 2006; 117: e577-e589.

22. Barroso O, Mazzoni I, Rabin O. Hormone abuse in sports: the antidoping perspective. Asian J Androl 2008; 10: 391-402.

23. Lange KHW, Larsson B, Flyvbjerg A, Dall R, Bennekou M, Rasmussen H, Ørskov H, Kjær M. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab 2002; 87: 4966-4975.

24. Hanukoglu A, Belutserkovsky O, Phillip M. Growth hormone activates renin-aldosterone system in children with idiopatic short stature and in a pseudohypoaldosteronism patient with a mutation in epithelial sodium channel alpha subunit. J Steroid Biochem Mol Biol 2001; 77: 49-57.

25. Fountoulakis S, Tsatsoulis A. Molecular genetic aspects and pathophysiology of endocrine hypertension. Hormones 2006; 5: 90-106.

26. Sesti G, Sciacqua A, Scozzafava A, Vatrano M, Angotti E, Ruberto C, Santillo E, Parlato G, Perticone F. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients. J Hypertens 2007; 25: 471-477.

27. Weltman A, Desprès JP, Clasey JL, Weltman JY, Wideman L, Kanaley J, Patrie J, Bergeron J, Thorner MO, Bouchard C, Hartman ML. Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults. Metabolism Clin Exper 2003; 52: 73-80.

28. Wideman L, Weltman JY, Hartman ML, Veldhuis JD, Weltman A. Growth hormone release during acute exercise and chronic aerobic and resistance exercise: recent findings. Sports Med 2002; 32: 987-1004.

29. Seo DI, Jun TW, Park KS, Chang H, So WY, Song W. 12 weeks of combined exercise is better than aerobic exercise for increasing growth hormone in middle-aged women. Int J Sport Nutr Exerc Metab 2010;20(1):21-26.

30. D’armiento M, Lenzi A, Luigi LD. Effect of supra-physiological dose administration of rGH on pituitary-thyroid axis in healthy male athletes. Regul Pept. Accepted: http://dx.doi.org/10.1016/j.regpep.2010.06.010

31. Machado M. O papel dos microtraumas e das células satélite na plasticidade muscular. Arq Movim 2007; 3: 103-117.

32. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp 2004; 262: 247-260.

33. Brown-Borg HM, Rakoczy SG, Sharma S, Bartke A. Long-living growth hormone receptor knock out mice: potential mechanisms of altered stress resistance. Exp Gerontol 2009; 44: 10-19.

34. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JMP, Martin RM. Circulating insulin-like growth factor (IGF) peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Canc 2009; 124: 2416-2429.

35. Fore J. Moving beyond gene doping: Preparing for genetic modification in sport. Virginia J Law Technol 2010; 15: 77-100.

36. Jia Y, Suzuki N, Yamamoto M, Gassmann M, Noguchi CT. Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage. Faseb J 2012; 26(7): 2847-2858.

37. Plenge U, Belhage B, Guadalupe- Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R. Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 2012; 3: 50. http://dx.crossref.org/10.3389/fphys.2012.00050 [08/11/2012].

38. Robinson N, Giraud S, Saudan C, Baume N, Avois L, Mangin P, Saugy M. Erythropoietin and blood doping. Brit J Sports Med 2006; 40(n.suppl.1): i30-i34.

39. Böning D, Maassen N, Pries A. The hematocrit paradox- how does blood doping really work? Int J Sports Med 2011; 32: 242-246.

40. Mancini DM, Katz SD, Lang CC, La- Manca J, Hudaihed A, Androne A-S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.

41. Desai A, Zhao Y, Lankford HA, Warren JS. Nitric-oxide suppresses EPO-induced monocyte-chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest 2006; 86: 369-379.

42. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscl Thromb Vasc Biol 2004; 24: 998-1005.

43. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762.

44. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytok Growth Fact Rev 2008; 19: 145-155.

45. Deo R, Khera A, McGuire DK, Murphy SA, Melo-Neto J de P, Morrow DA, Lemos JA de. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Amer Col Cardiol 2004; 44:1812-1818.

46. Brochu E, Lacasse-M S, Larivière R, Kingma I, Grose JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Amer Soc Nephrol 1999; 10: 1440-1446.

47. Rodrigue ME, Moreau C, Larivière R, Lebel M. Relationship between eicosanoids and endothelin-1 in erythropoietin-induced hypertension

in uremic rats. J Cardiovasc Pharmacol2003; 41: 388-395.

48. Olsen NV, Aachmann-Andersen N-J, Oturai P, Munch-Andersen T, Bornø A, Hulston C, Holstein-Rathlou N-H, Robach P, Lundby C. Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans. J Physiol 2011; 589: 1273-1281.

49. Lee MS, Lee JS, Lee JY. Prevention of erythropoietin-associated hypertension. Hypertension 2007; 50: 439-445.

50. Heinicke K, Baum O, Ogunshola OO, Vogel J, Stallmach T, Wolfer DP, Keller S, Weber K, Wagner PD, Gassmann M, Djonov V. Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. Am J Physiol Integr Comp Physiol 2006; 291: R947-R956.

51. Wang Y-Y, Jiao B, Guo W-G, Che H-L, Yu Z-B. Excessive thyroxine enhances susceptibility to apoptosis and decreases contractility of cardiomyocytes. Mol Cell Endocrinol 2010; 320: 67-75.

52. Chandra AK, Sinha S, Choudhury SR. Thyroxine induced stress and its possible prevention by catechin. Indian J Exp Biol 2010; 48: 559-565.

53. Layzer RB, Goldfield E. Periodic paralysis caused by abuse of thyroid hormone. Neurology 1974; 24: 949-952.

54. Wong P. Hypokalemic thyrotoxic periodic paralysis: a case series. Can J Emerg Med 2003; 5: 353-355.

55. Vale J, Canas N, Leal A, Vilar H. Paralisia periódica tireotóxica. Acta Méd Portug 2005; 18: 399-402.

56. Scally MC, Hodge A. A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). Int J Sport Nutr Exerc Metab 2003; 13: 112-116.

57. Pickett CA. An unusual case of central hypothyroidism and thyrotoxicosis factitia. Endocrinologist 2006; 16: 219-222.

58. Kumar HK, Yadav RK, Prajapati J, Reddy CV, Raghunath M, Modio KD. Association between thyroid hormones, insulin resistance, and metabolic syndrome. Saudi Med J 2009; 7: 907-911.

59. Kapadia KB, Bhatt PA, Shah JS. Association between altered thyroid state and insulin resistance. J Pharmacol Pharmacother 2012;3(2):156-160.